Cadila

Pharmaceutical company Zydus group on Wednesday announced that it had started the supply of its COVID-19 vaccine, ZyCoV-D, to the Central government against their order. The group is also planning to make the vaccine available in the…

PTI New Delhi, February 2Drug firm Zydus Cadila on Wednesday said it has commenced supplies of its Covid-19 vaccine ZyCoV-D to the central…

Zydus Cadila on Thursday said it has received final approval from the U.S. Food and Drug Administration (USFDA) to market Nelarabine Injection 250MG/50ML, in the US with 180 days of marketing exclusivity. The drugmaker said it is the first…

<!-- -->Zydus Cadila has agreed to reduce price of its vaccine doseZydus Cadila has agreed to bring down the price of its COVID-19 vaccine to Rs 265 a dose following persistent negotiations by the government but a final deal is yet to…

Health Minister says Cadila's COVID vaccine, ZyCov-D to be rolled out as part of India's vaccination programme soon and its pricing is under discussion. The vaccine ZyCoV-D received…

The Indian markets, taking mixed cues globally, are expected to open in the positive territory. This week meeting of central banks and the US Fed that is expected to announce something on the timeline of the tapering of asset purchase plan…

<!-- -->HCL Technologies has announced a five-year, digital transformation deal with MKS Instruments Inc.The domestic stock markets are likely to open in the green a day after falling around a per cent, going by early indications from…

The Indian market on Monday is expected to open on a flat note- thanks to mixed global cues. The market will behave cautiously as the US Fed is expected to meet this week and more clarity on tapering of asset purchase is expected to come…

The Indian markets, on Monday, taking negative global cues could open in the negative territory. The market is opening after being closed for three days. And as per many analysts, the market is expected to be in a range bound manner. At…

<!-- -->Shares of Cadila Healthcare surged as much as 8 per cent to hit an intraday high of Rs 576.25 after it received emergency use approval from Drug Controller General of India (DCGI) for its Coronavirus vaccine ZyCoV-D. . ZyCoV-D…